Structural Basis for Eculizumab-Mediated Inhibition of the Complement Terminal Pathway

Volume: 197, Issue: 1, Pages: 337 - 344
Published: Jul 1, 2016
Abstract
Eculizumab is a humanized mAb approved for treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Eculizumab binds complement component C5 and prevents its cleavage by C5 convertases, inhibiting release of both the proinflammatory metabolite C5a and formation of the membrane attack complex via C5b. In this study, we present the crystal structure of the complex between C5 and a Fab fragment with the...
Paper Details
Title
Structural Basis for Eculizumab-Mediated Inhibition of the Complement Terminal Pathway
Published Date
Jul 1, 2016
Volume
197
Issue
1
Pages
337 - 344
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.